Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.57 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13870842 | 0.88 | KMT2A (0.67) | MAPTGAAMEN1PKMKMT2A | |
| SCHEMBL13870767 | 0.86 | KMT2A (0.57) | GAAMEN1PKMKMT2AALDH1A1 | |
| SCHEMBL3503890 | 0.86 | MEN1 (0.63) | MEN1PKMKMT2AHTT | |
| SCHEMBL4092498 | 0.84 | KMT2A (0.60) | MAPTGAAMEN1PKMKMT2A | |
| SCHEMBL14855642 | 0.83 | KMT2A (0.79) | MAPTGAAMEN1PKMKMT2A | |
| SCHEMBL28745974 | 0.83 | GAA (0.79) | MAPTGAAKMT2AALDH1A1HPGD | |
| SCHEMBL13870851 | 0.83 | RAB9A (0.67) | MAPTGAAMEN1PKMKMT2A | |
| SCHEMBL10497116 | 0.82 | HCAR2 (0.78) | HCAR2RAB9ANPC1 | |
| SCHEMBL7244561 | 0.81 | ALDH1A1 (0.72) | MAPTGAAMEN1KMT2AALDH1A1 | |
| SCHEMBL2029098 | 0.79 | MEN1 (1.00) | MAPTMEN1PKMKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1758571-A1 | CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005115374-A1 | CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | NR1H2, NR1H3, HRH2 | MAPT 4833/4885GAA 4471/4885MEN1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.